OOIR: Observatory of International Research

Papers

(The TQCC of Seminars in Immunology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Antigen discovery for the development of cancer immunotherapy	132
The role of ILC subsets in cancer	111
Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy	98
DNGR-1-mediated cross-presentation of dead cell-associated antigens	82
Systems biology of B cells in COVID-19	70
Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells	66
Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases	60
Immune responses to SARS-CoV-2 infection and vaccination in children	57
Editorial Board	50
Introduction to the Special Issue: Immuno-oncology	50
Baseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS	46
Durability of immune responses to SARS-CoV-2 infection and vaccination	44
Editorial Board	43
Connecting the dots: Neutrophils at the interface of tissue regeneration and cancer	39
Genetics of Inborn Errors of Immunity in highly consanguineous Middle Eastern and North African populations	37
Systems analysis of innate and adaptive immunity in Long COVID	36
B cells and the intestinal microbiome in time, space and place	35
Multidimensional molecular controls defining NK/ILC1 identity in cancers	35
G-CSF, the guardian of granulopoiesis	33
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel	32
Accumulation of immune-suppressive CD4 + T cells in aging – tempering inflammaging at the expense of immunity	32
Toolkit for mapping the clonal landscape of tumor-infiltrating B cells	32
Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities	32
Thymus aging and immune reconstitution, progresses and challenges	31
Immunomodulatory effects of G-CSF in cancer: Therapeutic implications	30

Exploiting antifungal immunity in the clinical context	29
Versatile neutrophil functions in cancer	29
IL-33: A central cytokine in helminth infections	28
Harnessing TH9 cells in cancer immunotherapy	27
Cellular and Molecular Diversity in Scleroderma	27
High-throughput N-glycan analysis in aging and inflammaging: State of the art and future directions	26
Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients	26
Sialic acid and Siglec receptors in tumor immunity and immunotherapy	26
The origins, manifestations, and potential treatments of allergic disorders	26
Resolution pharmacology − A fresh approach to the clinical management of human inflammatory diseases	25
Microbial gasdermins: More than a billion years of pyroptotic-like cell death	25
Nanoparticles for generating antigen-specific T cells for immunotherapy	24
IL-1R8: A molecular brake of anti-tumor and anti-viral activity of NK cells and ILC	24
Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls	24
Recent developments in C3-targeted complement therapeutics	22
T cell immunity to SARS-CoV-2	22
Formyl peptide receptor 2 and heart disease	21
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology	21
The role of unconventional T cells in maintaining tissue homeostasis	21
Functions of macrophage colony-stimulating factor (CSF1) in development, homeostasis, and tissue repair	21
The neglected brothers come of age: B cells and cancer	20
Integrating immunopeptidome analysis for the design and development of cancer vaccines	19
Immune aging – A mechanism in autoimmune disease	19
Reparative inflammation in multiple sclerosis	19
The dual role of neutrophils in cancer	19
Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond	19
Pyroptosis-induced inflammation and tissue damage	19
NGS data analysis for molecular diagnosis of Inborn Errors of Immunity	18
The impact of immunopeptidomics: From basic research to clinical implementation	18
Inflammasomes as regulators of non-infectious disease	18
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion	17
Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet	17
Using mass spectrometry to identify neoantigens in autoimmune diseases: The type 1 diabetes example	16
The gut mucus network: A dynamic liaison between microbes and the immune system	15
Pyroptosis modulation by bacterial effector proteins	15
The tissue glycome as regulator of immune activation and tolerance mediated by C-type lectins and Siglecs	14
Editorial Board	14